← 홈

ADC · HER2+ 유방암

273개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 273개
ADCSHOTFDACuratedFDABiologicDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

HER2+ breast cancer, HER2-low, gastric · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 79.7%임상시험 224상태 APPROVED
ADCSHOTFDACuratedFDABiologicRocheMMAE (maytansinoid)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 80%임상시험 164상태 APPROVED
ADCSHOTFDACuratedFDABiologicRemeGenMMAEApproved

disitamab vedotin (Disitamab Vedotin, RC48)

HER2+ urothelial, gastric, breast · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 50%임상시험 153상태 ACTIVE
ADCSFDAFDABiologicFundación Pública Andaluza para…Deruxtecan-Dlnk Quantificat…Phase 3

Datopotamab deruxtecan (Datopotamab deruxtecan)

Breast Cancer; Metastatic Breast Cancer · Lung Cancer

#LungCancer#ADC#Phase3#FDA승인#항체약물접합체+5
효능 ORR 79%임상시험 44상태 RECRUITING
ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4
효능 ORR 71.7%임상시험 23상태 RECRUITING
ADCAHotBiologicImmunityBio, Inc.sPhase 3

Nab-paclitaxel (Nab-paclitaxel)

Triple Negative Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 69.1%임상시험 243상태 RECRUITING
ADCAHotBiologicCellerant TherapeuticsVedotin Therapy]Phase 3

Filgrastim (Filgrastim)

Male Breast Cancer; Stage II Breast Cancer · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 88%임상시험 170상태 RECRUITING
ADCAHotBiologicNCIC Clinical Trials Groupvedotin, 120 mg intr…Phase 3

Epirubicin (Epirubicin)

Breast Cancer · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 88.6%임상시험 133상태 RECRUITING
ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5
효능 ORR 80%임상시험 119상태 RECRUITING
ADCBBiologicstaleGileadaxisPhase 3

sacituzumab govitecan (Trodelvy)

Breast Cancer; Metastatic Breast Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 44%임상시험 87상태 RECRUITING
ADCSBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING
ADCABiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

T-DXd, DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (T-DXd, DS-8201a))

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING
ADCSBiologicRochederuxtecan (Dato-DXd, Datro…Phase 3

T-DXd (Trastuzumab-Deruxtecan, Trastuzumab-Deruxtecan (T-DXd))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 79.7%임상시험 83상태 RECRUITING
ADCBBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan (T-DXd) with pyrotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Approved#인기#항체약물접합체+4
효능 ORR 65.8%임상시험 78상태 RECRUITING
ADCCBiologicEli Lilly and CompanyPhase 2

Abemaciclib (Abemaciclib)

Advanced Cancer; Metastatic Melanoma · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 32.9%임상시험 77상태 RECRUITING
ADCCBiologicstaleHoffmann-La RochePhase 2

Cobimetinib (Cobimetinib)

Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma · Advanced Breast Carcinoma

#AdvancedBreastCarcinoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 67.6%임상시험 77상태 DISCONTINUED
ADCABiologicRocheDM1) and trastuzumab deruxt…Phase 3

ado-trastuzumab emtansine (Kadcyla, T-DM1)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 80%임상시험 76상태 RECRUITING
ADCCBiologicOHSU Knight Cancer InstitutePhase 2

Niraparib (Niraparib)

Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm · Advanced Breast Carcinoma

#AdvancedBreastCarcinoma#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 88%임상시험 75상태 DISCONTINUED
ADCBBiologicBristol-Myers SquibbDM4, indicating activation …Phase 2

Vemurafenib (Vemurafenib)

Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma · Advanced Breast Carcinoma

#AdvancedBreastCarcinoma#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 94%임상시험 74상태 DISCONTINUED
ADCBBiologicMerck Sharp & Dohme LLCPhase 2

Cytoxan (Cytoxan)

Multiple Myeloma, Refractory · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 95%임상시험 73상태 RECRUITING

1 / 14 페이지

← 이전다음 →